A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer
Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we developed a high-throughput drug screen strategy to identify new drugs that can enhance the sensitivity of chemo-drug cisplatin in SCLC. This screen identified auranofin, a US Food and Drug Administration (FDA)-approved drug used therapeutically for rheumatoid arthritis, as a sensitizer of cisplatin. Further study validated that auranofin synergistically enhanced the anti-tumor activity of cisplatin in chemo-resistant SCLC cells, which was accompanied by the enhanced induction of cell cycle arrest and apoptosis. The synergistic action of auranofin and cisplatin was through ROS overproduction, thereby leading to mitochondrial dysfunction and DNA damage. Furthermore, in vivo study demonstrated that the combination treatment of auranofin and cisplatin dramatically inhibited tumor growth in SCLC. Therefore, our study provides a rational basis for further clinical study to test whether auranofin could enhance the sensitivity of cisplatin-based therapy in SCLC patients.
KeywordsSmall cell lung cancer Ciplatin Auranofin ROS DNA damage
Small cell lung cancer
Non-small cell lung cancer
Food and Drug Administration
Mitochondrial membrane potential
This study was supported by National Natural Science Foundation of China (Grant Numbers: 81872438, 81672647, 81502632), Natural Science Foundation of Anhui Province (Grant Number: 1608085MH179), Science and Technology Major Project of Anhui Province (Grant Number: 18030801140), Science and Technology Service Network Initiative of Chinese Academy of Sciences (Grant Number: KFJ-STS-SCYD-010), Key program of 13th five-year plan of CASHIPS (Grant Number: KP-2017-26), and the 100-Talent Program of Chinese Academy of Sciences.
This study was supported by National Natural Science Foundation of China (Grant Numbers: 81872438, 81672647, 81502632), Natural Science Foundation of Anhui Province (Grant Number: 1608085MH179), Science and Technology Major Project of Anhui Province (Grant Number: 18030801140), Science and Technology Service Network Initiative of Chinese Academy of Sciences (Grant Number: KFJ-STS-SCYD-010), Key program of 13th five-year plan of CASHIPS (Grant Number: KP-2017-26), and the 100-Talent Program of Chinese Academy of Sciences..
Compliance with ethical standards
Conflict of interest
Authors have no financial/commercial conflicts of interest regarding the study.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
This article does not contain any studies with human participants performed by any of the authors.
- 6.Adhireksan Z, Palermo G, Riedel T, Ma ZJ, Muhammad R, Rothlisberger U, Dyson PJ, Davey CA (2017) Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat Commun 8:14860Google Scholar
- 8.Li H, Hu J, Wu SH, Wang L, Cao XB, Zhang XS, Dai BB, Cao MR, Shao RP, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan SY, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang BL (2016) Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548–3558PubMedGoogle Scholar
- 9.Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, Garcia-Rivera G, Orozco E, Martinez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18(6):956–960CrossRefGoogle Scholar
- 12.Zou P, Chen MX, Ji JS, Chen WQ, Chen X, Ying SL, Zhang JR, Zhang ZH, Liu ZG, Yang SL, Liang G (2015) Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget 6(34):36505–36521CrossRefGoogle Scholar
- 13.Wang H, Bouzakoura S, De Mey S, Jiang H, Law K, Dufait I, Corbet C, Verovski V, Gevaert T, Feron O, Van den Berge D, Storme G, De Ridder M (2017) Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species. Oncotarget 8(22):35728–35742PubMedPubMedCentralGoogle Scholar
- 17.Wangpaichitr M, Wu C, You M, Maher JC, Dinh V, Feun LG, Savaraj N (2009) N',N'-dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) selectively kills cisplatin resistant lung Cancer cells through reactive oxygen species (ROS). Cancers 1(1):23–38. https://doi.org/10.3390/cancers1010023 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Luo M, Shang L, Brooks MD, Jiagge E, Zhu YY, Buschhaus JM, Conley S, Fath MA, Davis A, Gheordunescu E, Wang YF, Harouaka R, Lozier A, Triner D, McDermott S, Merajver SD, Luker GD, Spitz DR, Wicha MS (2018) Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. Cell Metab 28(1):69–86. https://doi.org/10.1016/j.cmet.2018.06.006 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng QH, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B (2019) Inhibition of Thioredoxin/Thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis. Cancer Res 79(1):125–132. https://doi.org/10.1158/0008-5472.CAN-18-1938 CrossRefPubMedGoogle Scholar
- 21.Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, Baille D, Masson V, Dingli F, Loew D, Azzarone B, Eid P, Baldacci G, Huang ME (2018) Auranofin/vitamin C: a novel drug combination targeting triple-negative breast Cancer. J Natl Cancer Inst. https://doi.org/10.1093/ije/djy149
- 23.Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KN (2014) Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 74(9):2520–2532. https://doi.org/10.1158/0008-5472.CAN-13-2033 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Chiu WH, Luo SJ, Chen CL, Cheng JH, Hsieh CY, Wang CY, Huang WC, Su WC, Lin CF (2012) Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochem Pharmacol 83(9):1159–1171. https://doi.org/10.1016/j.bcp.2012.01.016 CrossRefPubMedGoogle Scholar